Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Zenocutuzumab Now FDA-Approved in NRG1+ NSCLC and …
Dec 4, 2024 · The FDA has approved zenocutuzumab (formerly MCLA-128) for the treatment of patients with neuregulin 1 fusion (NRG1+) non–small cell lung cancer (NSCLC) and NRG1+ pancreatic ductal adenocarcinoma (PDAC).The approval is supported by the phase 1/2 eNRGy trial (NCT02912949).
Positive Trials Continue to Shape the SCLC Treatment Landscape
Nov 8, 2024 · Recent advancements in small cell lung cancer (SCLC) treatments have introduced transformative therapies and trial results, according to Ariel Lopez-Chavez MD.
Therapies With Different Mechanisms of Action Available for Low …
Dec 3, 2024 · The FDA granted fast track designation to NX-5948 for treating relapsed/refractory Waldenström macroglobulinemia after 2 or more lines of therapy, including a BTK inhibitor.
Dato-DXd Shows Promising Efficacy in Endometrial and Ovarian …
Sep 15, 2024 · The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 (NCT05489211) study presented at the 2024 ESMO Congress. 1
Antibody-Drug Conjugates Show Unique Advantage in Breast …
Nov 19, 2024 · Erika P. Hamilton, MD, director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute, discusses antibody-drug conjugates (ADCs) in multiple types of breast cancer, and when to use these drugs in sequence.
Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung …
Dec 4, 2024 · The FDA has approved durvalumab (Imfinzi) for the treatment of limited-stage small cell lung cancer (SCLC) that has not progressed following platinum-based concurrent chemoradiotherapy.
GD2-CAR T Induces Tumor Regression in H3K27M-Mutant Diffuse …
Nov 25, 2024 · A phase 1 clinical trial (NCT05316155) investigating the use of GD2-targeted chimeric antigen receptor (CAR) T cells for the treatment of H3K27M-mutant diffuse midline gliomas (DMGs) yielded promising results, demonstrating the feasibility, safety, and early efficacy of this approach. 1. The trial enrolled 13 patients, with 11 receiving GD2-CAR T-cell therapy.
HBI-8000 Plus Nivolumab Is Safe, Active in Melanoma
Dec 2, 2024 · Combining the novel agent HBI-8000 with nivolumab (Opdivo) showed promising efficacy and tolerability in patients with melanoma and no prior anti–PD-1/PD-L1 treatment, according to findings from a phase 2 trial presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. 1,2 A total of 39 eligible patients were enrolled in the study and treated with HBI-8000 at 30 mg ...